PolyPid (PYPD) Stock Forecast & Price Target

PolyPid is compelling because D-PLEX100 has replicated late-stage efficacy, cutting incisional surgical-site infections by about 60% in SHIELD II and earning FDA Priority Review with a November 28, 2026 PDUFA date, while the remaining approval risk is mainly limited to CMC and inspection items. Its economics are also attractive: Azurity has already paid $30M, may contribute over $290M in milestones, and PolyPid retains mid-teen to mid-20s royalties plus manufacturing transfer revenue, which together appear undervalued versus the company’s roughly $100M EV. Beyond the initial colorectal opportunity, a measured 2027 launch, possible NTAP reimbursement from 4Q27, and broader label or platform expansion provide additional upside without requiring PolyPid to build a costly commercial organization.

PolyPid is viewed negatively because its core value driver, D-PLEX100, still faces major regulatory and execution risk, with FDA review pending and a November 28, 2026 PDUFA date that could still end in a CRL, added study, or a restrictive label. Even if approved, CMS denial of NTAP on cost would force hospitals to absorb the full product cost, while slow P&T reviews, limited surgeon adoption, and Azurity’s undisclosed commercialization economics could keep penetration in the low single digits through 2028. The company also retains manufacturing and financing risk, since production remains in Israel and any approval delay, supply disruption, or weaker uptake could raise cash needs and force dilutive financing.